Novel CD22 CAR-T Works After CD19 Product Failed Novel CD22 CAR-T Works After CD19 Product Failed
A novel CAR T-cell therapy directed against CD22 worked in children with acute lymphoblastic leukemia who had previously progressed after receiving CD19-directed CAR T-cell therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

University of Colorado Cancer Centers Study Shows that without “Yoga...
Researchers successfully target leukemia stem cells while leaving healthy blood stem cells unharmed, paving the way for "sea change" in the way we treat acute myeloid leukemia.(PRWeb June 14, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15553957.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2018 Category: Pharmaceuticals Source Type: news

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions
(University of Texas M. D. Anderson Cancer Center) Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2018 Category: Cancer & Oncology Source Type: news

Penn-developed approach could limit toxicity of CAR T therapy in acute myeloid leukemia
(University of Pennsylvania School of Medicine) A new approach pioneered at the University of Pennsylvania's Abramson Cancer Center may provide a new path towards treating acute myeloid leukemia (AML) with CAR T cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority R... Biopharmaceuticals, Oncology, FDA Astellas Pharma, gilteritinib, Acute Myeloid Leukemia, FLT3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 29, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 29, 2018 Category: Drugs & Pharmacology Source Type: news

' Too Clean' Could Be a Trigger for Childhood Acute Leukemia'Too Clean' Could Be a Trigger for Childhood Acute Leukemia
A lack of microbial exposure among children in industrialized countries may contribute to the development of childhood B-cell acute lymphoblastic leukemia, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Early exposure to microbes may protect against childhood leukemia
A new analysis suggests that childhood acute lymphoblastic leukemia likely results from genetic predisposition and limited early exposure to germs. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 23, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

New 'unified theory' of childhood leukemia raises possibility of preventing the disease
Kids who develop acute lymphoblastic leukemia may be the victims of a triple-whammy stroke of bad luck, according to a provocative new theory from a respected British cancer researcher.If the explanation turns out to be correct, it would be good news for the most common type of childhood cancer:... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - May 23, 2018 Category: Science Authors: Melissa Healy Source Type: news

Imatinib-induced Fulminant Liver Failure in CML Imatinib-induced Fulminant Liver Failure in CML
Acute liver failure can be a fatal adverse effect of chronic myeloid leukemia treatment with imatinib. Is liver transplant a viable option for these patients?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

' Best Survival Data Ever' in Young T-Cell Leukemia Patients'Best Survival Data Ever' in Young T-Cell Leukemia Patients
Moving nelarabine to the front line and combining it with methotrexate improved 4-year disease-free survival in young patients with T-cell acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ultra-Clean Homes Can Raise Childhood Cancer Risk, Study Finds
LONDON (CBS Local) – A groundbreaking study into what triggers cancer has found that children who are “too hygienic” and are kept away from other kids were at greater risk for developing leukemia. The Details: A cancer study has found that children living in ultra-clean environments have higher rates of leukemia Professor Mel Greaves says children need to have their immune system “primed” by exposure to various germs Greaves found that children with siblings or who were breastfed had lower rates of the disease Professor Mel Greaves from the Institute of Cancer Research (ICR) in London h...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News childhood cancer Children Chris Melore Germs Leukemia Local TV talkers Source Type: news

Most common childhood cancer 'partly caused by lack of infection'
Childhood acute leukaemia is caused by genetic mutations and a lack of childhood infection, scientists sayClean modern homes, antiseptic wipes and the understandable desire to protect small babies against any infection are all part of the cause of the most common form of childhood cancer, a leading expert has concluded after more than 30 years of research.Childhood acute leukaemia, says the highly respected Prof Mel Greaves, is nothing to do with power lines or nuclear fuel reprocessing stations. Nor is it to do with hot dogs and hamburgers or the Vatican radio mast, as have also been suggested. After the best part of a ce...
Source: Guardian Unlimited Science - May 21, 2018 Category: Science Authors: Sarah Boseley Health editor Tags: Cancer Health Cancer research Medical research Science Society Children Source Type: news

Leading UK scientist reveals likely cause of childhood leukaemia
(Institute of Cancer Research) A major new analysis reveals the likely cause of most cases of childhood leukaemia, following more than a century of controversy about its origins.Professor Mel Greaves assessed the most comprehensive body of evidence ever collected on acute lymphoblastic leukaemia (ALL). He concludes the disease is caused through a two-step process of genetic mutation and exposure to infection that means it may be preventable with treatments to stimulate or 'prime' the immune system in infancy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 21, 2018 Category: Biology Source Type: news

A new Achilles' heel of blood cancer
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Acute Myeloid Leukemia is an aggressive form of blood cancer. The diseased cells often carry mutated forms of a specific gene, which is known to function within large protein networks. Applying a combination of proteomic and genomic screens, researchers at CeMM and LBI-CR identified a protein crucial for the survival of the cancer cells. When this protein is lost, AML cells stop growing and accumulate DNA damage, which makes them more sensitive to anti-cancer drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 18, 2018 Category: Cancer & Oncology Source Type: news

Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia
(Rockefeller University Press) Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 17, 2018 Category: Biology Source Type: news

New regimens improve survival for children and young adults with T-cell cancers
(American Society of Clinical Oncology) In a federally funded, randomized phase III clinical trial performed by the Children's Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84 percent were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

Leukemia: Five easily overlooked signs you have the condition
LEUKEMIA, or blood cancer, symptoms are not always easily detected. The condition has several forms including acute myeloid leukaemia and chronic leukemia. You should look out for these five symptoms of the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - May 10, 2018 Category: Consumer Health News Source Type: news

New CAR T case study shows promise in acute myeloid leukemia
(H. Lee Moffitt Cancer Center& Research Institute) According to a case study from trial published online ahead of print in the journal Haematologica, a patient has remained cancer free for nine months after being treated with CYAD-01, followed by a bone marrow transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news

Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Quizartinib is the first FLT3 inhibitor to demonstrate improved overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations, a very aggressive form of the disease associated with poo... Biopharmaceuticals, Oncology Daiichi Sankyo Company, quizartinib, acute myeloid leukemia, FLT3 inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2018 Category: Pharmaceuticals Source Type: news

Leukemia protective role of Y chromosome gene discovered
(Wellcome Trust Sanger Institute) Scientists have discovered the first leukemia protective gene that is specific to the male-only Y chromosome. Researchers at the Wellcome Sanger Institute and the University of Cambridge found that this Y-chromosome gene protects against the development of acute myeloid leukemia (AML) and other cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 7, 2018 Category: Biology Source Type: news

Crucial Mutations Found in T-Cell ALL
T-ALL may be treatable by targeting signaling pathways affected by STIL-TAL1 fusion, according to a team from The Institute of Cancer Research, London, UK. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Lymphoblastic Leukemia News Source Type: news

Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Cancer cell cycle inhibitor is Lin BioScience's second candidate to receive Orphan Drug Designation SAN DIEGO, April 24, 2018 -- (Healthcare Sales & Marketing Network) -- Lin BioScience, a drug development company targeting unmet clinical needs in onco... Biopharmaceuticals, Oncology, FDA Lin BioScience, LBS-007, acute lymphoblastic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 24, 2018 Category: Pharmaceuticals Source Type: news

Novel pathway identified in development of acute myeloid leukemia with poor prognosis
(National University of Singapore, Yong Loo Lin School of Medicine) NUS researchers have discovered a new pathway by which a severe form of acute myeloid leukemia (AML) develops. The main player in the pathway, a protein called SHARP1, promotes leukemia development and maintenance, both on its own and through its actions on other genes. The discovery could lead to the development of novel SHARP1-specific treatments for this difficult-to-treat form of AML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 24, 2018 Category: Biology Source Type: news

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
TOKYO, April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 23, 2018 Category: Drugs & Pharmacology Source Type: news

What Causes Hyponatremia?
Discussion Normal kidneys regulate water balance to maintain a plasma osmolality of 275-290 mOsm/kg normally. Thirst and arginine vasopressin or antidiuretic hormone (ADH) are the primary regulators of plasma osmolality. ADH is made in the hypothalamus and released by the posterior pituitary gland. ADH acts on the kidney’s distal collecting duct to increase water reabsorption. ADH is appropriately released in hypovolemic states, such as dehydration caused by gastroenteritis. ADH has an ~10 minute half-life and therefore can respond to rapid changes in volume status. Sodium balance is regulated by aldosterone (as part...
Source: PediatricEducation.org - April 23, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

BIDMC-lead team develops new approach to study long non-coding RNAs
(Beth Israel Deaconess Medical Center) In a groundbreaking paper, investigators at the Cancer Research Institute Beth Israel Deaconess Medical Center developed a novel approach to identify and determine the functional role of lncRNAs relevant to chemotherapy resistance in Acute Myeloid Leukemia (AML). The new technique integrates information from publicly-available pharmacological data bases with leading-edge CRISPR technologies to screen for both coding and non-coding genes that influence response to treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2018 Category: Cancer & Oncology Source Type: news

For young adults with blood cancer, pediatric centers may improve survival
(American Society of Hematology) Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 18, 2018 Category: Cancer & Oncology Source Type: news

Implications of Mutation Profiling in Myeloid Malignancies —PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Acute Myeloid Leukemia Hematologic Malignancies Myelodysplastic Syndromes Oncology Journal Review Article Source Type: news

Novel Drug Shows Promise Against Acute Myeloid Leukemia
April 11, 2018—(BRONX, NY)—In a study published online today in Science Translational Medicine,Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway atMontefiore Health System. (Source: Einstein News)
Source: Einstein News - April 11, 2018 Category: Universities & Medical Training Source Type: news

Novel drug shows promise against acute myeloid leukemia
(Albert Einstein College of Medicine) In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway at Montefiore Health System. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2018 Category: Cancer & Oncology Source Type: news

Targeting JAK3 and HOXA9 to Combat T-Cell ALL?
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Lymphoblastic Leukemia Hematologic Malignancies News Source Type: news

Inspirational cancer victim DIES months after having an abortion
Charlotte Smith, from North Yorkshire, was diagnosed with acute lymphoblastic leukaemia when she was 11 weeks pregnant. Doctors warned carrying a child posed a danger to her life. (Source: the Mail online | Health)
Source: the Mail online | Health - April 10, 2018 Category: Consumer Health News Source Type: news

Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
First Data Presentations for CAR T Programs, Including DLL3 in Small Cell Lung Cancer and FLT3 in Acute Myeloid Leukemia Pre-Clinical Data Evaluating Half-Life Extended Anti-BCMA BiTE® Presented for First-Time New Data Include two Studies Investigating Mcl-1 Inhibitor AMG 176 THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's ...
Source: Amgen News Release - April 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

CAR T-Cell Therapy in ALL: Formidible Challenges Remain
At the NCCN Annual Conference, Dr. Bijal Shah of Tampa ’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2018 Category: Cancer & Oncology Authors: Roxanne Nelson Tags: Acute Lymphoblastic Leukemia Conferences/NCCN News Source Type: news

FDA Expands Blinatumomab Approval for ALL to Include MRD
The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD. (Source: CancerNetwork)
Source: CancerNetwork - April 3, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Acute Lymphoblastic Leukemia Hematologic Malignancies News Source Type: news

Blincyto OK'd for MRD-Positive Acute Lymphoblastic Leukemia
(MedPage Today) -- Residual disease undetectable in 70 of 86 patients treated (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 29, 2018 Category: American Health Source Type: news

FDA Approves BLINCYTO ® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease Detection of Remaining Cancer Cells After Complete Remission is the Strongest Prognostic Factor for Relapse in Patients With Acute Lymphoblastic Leukemia Accelerated Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., March 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (bl...
Source: Amgen News Release - March 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Blincyto Approval Expanded for Specific Leukemia
THURSDAY, March 29, 2018 -- The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who still have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 29, 2018 Category: General Medicine Source Type: news

FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
March 29, 2018 -- The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 29, 2018 Category: Drugs & Pharmacology Source Type: news

New Approach to Assessing MRD in Acute Leukemia New Approach to Assessing MRD in Acute Leukemia
Minimal residual disease, a benchmark for identifying patients who are at risk for relapse, is typically done using flow cytometry. Next-generation sequencing now refines the process with additional mutations thrown into the mix.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Molecular Minimal Disease in Remission Predicts AML Relapse
WEDNESDAY, March 28, 2018 -- The detection of molecular minimal residual disease is associated with increased relapse rates in acute myeloid leukemia (AML), according to a study published in the March 29 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2018 Category: Pharmaceuticals Source Type: news

Childhood Acute Myeloid Leukemia (AML)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 23, 2018 Category: General Medicine Source Type: news

Two genes cooperate to trigger leukemia development
(VIB (the Flanders Institute for Biotechnology)) An international group of researchers led by Professor Jan Cools of the VIB-KU Leuven Center for Cancer Biology have made a breakthrough in understanding the development of acute lymphoblastic leukemia, an aggressive cancer of the blood. While scientists were already familiar with many cancer-causing genes and their separate functions, the VIB team has now illustrated how two of these cancer genes work together to trigger leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 20, 2018 Category: Cancer & Oncology Source Type: news

A Diagnostic Dilemma: Sometimes You ’ ll Never Know
Patient Presentation A 9-year-old male came to clinic with a 1 month history of painful joint swelling. One month ago he started having right ankle pain that was intermittent but consistent. One day ago his right wrist, right ankle and bilateral knees had some swelling but no erythema or warmth. He says that he has pain in them when he moves but not when he is resting and he denies any joint stiffness or gelling. He also had 1-2 days of multiple red skin lesions on his extremities and trunk, not overlying the affected joints. The skin lesions do not come and go and do not itch. They are mainly discrete circular lesions wi...
Source: PediatricEducation.org - March 19, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Huntsman Cancer Institute joins national clinical trial targeting AML
(Huntsman Cancer Institute) Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia& Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2018 Category: International Medicine & Public Health Source Type: news

Targeting Cholesterol Pathway Shows Potential for AML Treatment
Researchers have discovered that AML cells require high levels of cholesterol for survival, so the cholesterol pathway could represent a potential therapeutic option for the disease. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Myeloid Leukemia Hematologic Malignancies News Source Type: news

FDA Panel Gives Nod to New Blincyto Use in ALL FDA Panel Gives Nod to New Blincyto Use in ALL
Blinatumomab would become the first treatment for which minimal residual disease positivity would be a selection criterion and MRD negativity an endpoint for acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news